C07K 9/003
Peptides being substituted by heterocyclic radicals
Official title: {Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin}
C07K9/003 (Peptides being substituted by heterocyclic radicals) appears on 68 US grants and 58 published applications in this corpus.
Search patents in C07K- Granted patents
- 68
- Published applications
- 58
- Assignees
- 58
- Inventors
- 211
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 4 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 4 | 4 |
| 2004 | 1 | 2 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 1 | 12 |
| 2008 | 1 | 3 |
| 2009 | 3 | 1 |
| 2010 | 1 | 3 |
| 2011 | 0 | 0 |
| 2012 | 2 | 0 |
| 2013 | 2 | 1 |
| 2014 | 1 | 1 |
| 2015 | 1 | 3 |
| 2016 | 0 | 3 |
| 2017 | 0 | 1 |
| 2018 | 2 | 4 |
| 2019 | 1 | 2 |
| 2020 | 6 | 1 |
| 2021 | 2 | 7 |
| 2022 | 2 | 1 |
| 2023 | 0 | 3 |
| 2024 | 1 | 1 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same2 Sep 2025US 12,404,304 B1Sierra Sciences, Inc.
- Hemiasterlin derivatives for conjugation and therapy9 Jan 2024US 11,866,515 B2Sutro Biopharma, Inc.
- Third generation tubulysin analogues and process of preparation thereof6 Dec 2022US 11,518,786 B2Indian Institute of Technology Indore
- Supramolecular glycosaminoglycans15 Nov 2022US 11,497,788 B2Northwestern University
- Peptides with anti-cancer activity28 Dec 2021US 11,207,379 B2Idp Discovery Pharma, S.L.
- Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereof8 Jan 2026US 2026/0007758 A1Crinetics Pharmaceuticals, Inc.
- B7h3 antibody drug conjugates9 Oct 2025US 2025/0312473 A1BeOne Medicines I GmbH
- Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same5 Jun 2025US 2025/0179122 A1Sierra Sciences, Inc.
- Hemiasterlin derivatives for conjugation and therapy1 Aug 2024US 2024/0254163 A1Sutro Biopharma, Inc.
- Site-specific antibody conjugates and the methods for preparation of the same27 Jul 2023US 2023/0235082 A1Glyco-Therapy Biotechnology Co., Ltd.
Most cited
By later US patents
- Glycoconjugates of modified camptothecin derivatives (A-or B-ring linkage)82US 6,156,754 ABayer Aktiengesellschaft · 2000
- 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections72US 7,625,875 B2Centre National De La Recherche Scientifique · 2009
- 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections70US 7,456,155 B2Centre National De La Recherche Scientifique · 2008
- Camptothecin derivatives61US 5,837,673 ATanabe Seiyaku Co., Ltd. · 1998
- 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections60US 7,662,798 B2Centre National De La Recherche Scientifique · 2010